See total ranking

Daiichi Sankyo

Assessed in 2022

Daiichi Sankyo is a pharmaceutical group founded in 2005 and headquartered in Tokyo, Japan. It is the second largest pharmaceutical company in the country. The group encompasses 52 companies with a presence across 26 different countries. It employs more than 16,000 people around the world. In 2021 the company generated almost US$10 billion in revenue.

Summary

The overall average score across all 2,000 companies is 4.5 out of 20. The average scores by measurement area are: respect human rights, 2.4 out of 10; provide and promote decent work, 1.2 out of 6; and act ethically, 0.9 out of 4.

The first measurement area reflects the expectations on businesses to commit to internationally recognised human and labour rights, implement a human rights due diligence process and ensure access to remedies. The second measurement area addresses critical issues such as safe and healthy workplaces, living wages and working hours, collective bargaining, and diversity and inclusion. The third measurement area encompasses ethical behaviour on topics such as data privacy, corporate taxation, bribery and corruption, and lobbying and political engagement.

More detailed information on this company’s performance can be found in the dataset below. More information about the overall trends and performance of the 2,000 companies can be found in the Social Benchmark 2024 Insights Report.

Download full data set (xls)

Total score: 5.5 /20

Measurement theme	Score
Respect human rights	1.5 /10
Provide and promote decent work	2.0 /6
Act ethically	2.0 /4

Measurement theme

Score

Respect human rights

1.5 /10

Provide and promote decent work

2.0 /6

Act ethically

2.0 /4

More about the company

Headquarters: Japan

This company is part of the SDG2000, the 2,000 most influential companies globally

See company profile SDG2000